Immuno-Oncology | Specialty

Expert Says Nivolumab Poised to Change Standard of Care in SCCHN

August 23rd 2016

Robert L. Ferris, MD, PhD, discusses the findings of the CheckMate-141 study, potential biomarkers for nivolumab (Opdivo), and questions that remain regarding the use of the immunotherapy in squamous cell carcinoma of the head and neck.

Dr. Gadgeel on Pembrolizumab/Chemo Combo in NSCLC

August 23rd 2016

Shirish Gadgeel, MD, medical oncologist, leader of the Thoracic Oncology Multidisciplinary Team at Karmanos Cancer Institute, Wayne State University, discusses the KEYNOTE-021 study, which is examining the combination of pembrolizumab (Keytruda) and chemotherapy as a potential treatment for patients with non–small cell lung cancer.

Pembrolizumab to Have Critical Role in Head and Neck Cancer Treatment

August 21st 2016

Joshua M. Bauml, MD, discusses the impact of pembrolizumab's (Keytruda's) success in recurrent or metastatic head and neck squamous cell carcinoma, the results of the KEYNOTE-055 study, and what he sees on the horizon for the PD-1 inhibitor in this field.

Dr. Jeffrey S. Weber on Why the Results of CheckMate-064 Were Surprising

August 21st 2016

Dr. Edward S. Kim on his "Wish List" for the Future of Immunotherapy in NSCLC

August 18th 2016

Dr. Joshua M. Bauml on Pembrolizumab Versus Chemo in Head and Neck Cancers

August 16th 2016

Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the differences between pembrolizumab (Keytruda) and cytotoxic chemotherapies.

Going Beyond PD-L1 for Predictive Biomarkers in Lung Cancer

August 15th 2016

Biomarkers, such as immune cell PD-L1 expression, mutational burden, and immune system activation should be investigated further to clarify the mechanisms behind response and nonresponse to immunotherapy in patients with lung cancer.

Investigator Highlights Remarkable Responses With Pembrolizumab in Sarcoma

August 12th 2016

Treatment with pembrolizumab (Keytruda) led to a reduction of tumor size in 33% of patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Immunotherapy Transforms Melanoma Care, But Challenges Remain

August 12th 2016

Norman E. Sharpless, MD, discusses the impact of the CheckMate-069 trial, the toxicities that are associated with nivolumab (Opdivo)/ipilimumab (Yervoy), and what the future holds for immunotherapy combinations in the field of melanoma.

Bunn Discusses Frontline Nivolumab NSCLC Results, Issues With PFS Endpoint

August 11th 2016

Paul A. Bunn Jr, MD, discusses the meaning of the CheckMate-026 results with frontline nivolumab in NSCLC and issues with the trial's primary endpoint of progression-free survival.

Expert Explores Next Steps With "Game Changer" Atezolizumab in Bladder Cancer

August 11th 2016

Gary D. Steinberg, MD, discusses the impact of atezolizumab (Tecentriq) on the treatment landscape of bladder cancer, the resistance to finding effective therapies for the disease, and what potential role immunotherapy may have in the field going forward.

Immunotherapy Advances Again Propel Progress in GU Malignancies

August 11th 2016

Randy F. Sweis, MD, covers the immunotherapy advancements in prostate cancer, renal cell carcinoma, and bladder cancer, and what refinement lies ahead in each of these areas.

Optimal Therapy Sequence Continues to Evolve for Advanced NSCLC

August 9th 2016

The past few years have seen rapid evolution in the treatment and handling of advanced non–small cell lung cancer, prompting questions on how to optimize immunotherapies and targeted agents as well as incorporate biomarker testing.

Combination of Immunotherapy and Lung Cancer Therapies Potential Game-Changer, But Needs Further Research

August 9th 2016

Paul A. Bunn Jr, MD, discussed how combining immunotherapy with chemotherapy, molecular therapy, or anti-angiogenic therapy has shown promising results in recent randomized trials of patients with lung cancer, although the combinations have yet to demonstrate clear superiority.

CheckMate-026 Underscores Predictive Value of High PD-L1 Expression

August 9th 2016

The value of PD-L1 expression when using checkpoint inhibitors in non–small cell lung cancer is underscored by the just-announced disappointing progression-free survival findings from the phase III CheckMate-026 study of frontline nivolumab (Opdivo) versus physician's choice of combination chemotherapy.

Weber Discusses Sequential Versus Concurrent Immunotherapy in Melanoma

August 9th 2016

Jeffery S. Weber, MD, PhD, discusses findings from the phase II CheckMate-064 trial, in which patients were randomized to receive either nivolumab followed by ipilimumab followed by nivolumab maintenance therapy, or ipilimumab followed by nivolumab and maintenance therapy with nivolumab.

FDA Approves Pembrolizumab for Head and Neck Cancer

August 6th 2016

The FDA has granted an accelerated approval to pembrolizumab as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma following progression on a platinum-based chemotherapy.

Dr. Ferris on FDA Approval of Pembrolizumab in Head and Neck Cancer

August 6th 2016

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the impact of the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with head and neck cancer.

Dr. Bunn on Missed Endpoint for Nivolumab in CheckMate-026 for NSCLC

August 5th 2016

Paul A. Bunn Jr, MD, Distinguished Professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the phase III results from CheckMate-026, which explored nivolumab (Opdivo) monotherapy in treatment-naïve patients with advanced non–small cell lung cancer.

Dr. David F. McDermott on Nivolumab in RCC

August 5th 2016